CD4 and melanoma: The Advisory Committee of Spanish Melanoma Group recently reviewed available data and made recommendations for the treatment and monitoring of melanoma patients with HIV who receive ICIs (19), summarized as follows: ICIs should be administered in people with HIV when the HIV viral load is undetectable and in patients receiving ART who have CD4+ T-cell counts ideally above 200 cells per mm3.